Xoma Royalty Corporation · NASDAQ:XOMA
Xoma Royalty — XOMA — Investor Presentation (August 2023)
24 slides from Xoma Royalty's investor presentation, August 2023
Slide 1: Corporate Presentation: The Royalty Aggregator for Biotech Companies
CORPORATE PRESENTATION THE ROYALTY AGGREGATOR FOR BIOTECH NASDAQ: XOMA COMPANIES AUGUST 2023
Slide 2: Disclaimers
DISCLAIMERS Certain statements in this presentation are forward-looking Any forward-looking statements represent XOMA’s views only as of statements within the meaning of Section 27A of the Securities Act of the date of this presentation and should not be relied upon as 1933 and Section 21E of the Se
Slide 3: Opportunities Abound for Royalty Monetization
OPPORTUNITIES ABOUND FOR ROYALTY MONETIZATION License LIFE SCIENCES INDUSTRY LICENSING DEALS ANNUALLY transactions 2014 – 2022 consist of: 645 648 ▪ Upfront payment 620 585 ▪ Milestone payments 548 522 ▪ Royalty obligations 459 475 404 2014 2015 2016 2017 2018 2019 2020 2021 2022 Bloomberg data 3
Slide 4: We Buy Royalties & Buybacks
WE BUY: RO Y AL TIES & BIO U B CK S 4
Slide 5: XOMA's Ideal Asset
XOMA’S IDEAL ASSET STRONG DEVELOPER/MARKETER Assets partnered with high-quality pharma / biopharma companies MID- TO EARLY-STAGE CLINICAL ASSETS Rx Therapeutic area agnostic LONG DURATION OF MARKET EXCLUSIVITY Patent expiration or regulatory exclusivity HIGH REVENUE POTENTIAL High unmet need or clea
Slide 6: Basics of a XOMA Royalty Monetization Transaction
BASICS OF A XOMA ROYALTY MONETIZATION TRANSACTION STEP 1: STEP 2: Capital BIOTECH Royalties & Milestones Program Royalties & Licensed Milestones BIG PHARMA 6
Slide 7: Actively Acquiring New Royalties
ACTIVELY ACQUIRING NEW ROYALTIES SELLER PARTNER / LICENSEE # ASSETS CAPITAL DEPLOYED THERAPEUTIC AREA or INDICATION(s) $14M Affitech 1 ($6M upfront, $5M at FDA approval, wAMD, DME, other retinal conditions $3M at EU approval) Aptevo 1 $9.6M Hemophilia B LadRx 2 $5M Niemann-Pick Type C, pancreatic ca
Slide 8: Arimoclomol + Aldoxorubicin Transaction
ARIMOCLOMOL + ALDOXORUBICIN TRANSACTION: $5M outlay to LadRx1 $396M potential milestones Mid-single to mid-teens royalties Arimoclomol will be a first-in-class therapy if approved by regulatory authorities for NPC. Zevra preparing NDA filing for arimoclomol in Niemann-Pick disease Type C (NPC) 2 Imm
Slide 9: Ixinity Transaction
IXINITY TRANSACTION: ® $9.6M outlay to Aptevo Mid-single digit royalties on sales beginning 1/1/2023 into 1Q2035 Marketed in the U.S. by Medexus for the control and prevention of bleeding episodes and postoperative management in people with Hemophilia B 9
Slide 10: Ebopiprant Transaction
EBOPIPRANT TRANSACTION: $15M outlay to ObsEva $378M potential milestones Mid-single to low-teens royalty, net Organon secured development & commercialization license from ObsEva in July 2021 “This development-stage asset is being studied in one of the most crucial unmet needs for women globally. As
Slide 11: XOMA Is Differentiated in Royalty Space
XOMA IS DIFFERENTIATED IN ROYALTY SPACE Capital per transaction $200M + Royalty Pharma $100M – DRI $200M Healthcare Trust $25M – FOCUSED ON Ligand $100M MID- TO EARLY-STAGE CLINICAL ASSETS HCRP < $25M PRECLINICAL PHASE 1 PHASE 2 PHASE 3 APPROVAL COMMERCIAL 11
Slide 12: Royalty Monetization - Increasingly in Focus
ROYALTY MONETIZATION - INCREASINGLY IN FOCUS 12
Slide 13: Royalty Monetization Increasingly More Attractive
ROYALTY MONETIZATION INCREASINGLY MORE ATTRACTIVE Source: The Brookline Brief, November 2, 2022 13
Slide 14: XOMA Snapshot: 70+ Assets
XOMA SNAPSHOT Portfolio of ▪ Acquire drug royalties + milestones associated with mid- to early stage clinical candidates 70+ ASSETS – Differentiate by focusing on development-stage assets in >30 disclosed indications with blockbuster potential licensed to large-cap partners today and growing ▪ Provi
Slide 15: Key XOMA Portfolio Assets
KEY XOMA PORTFOLIO ASSETS https://www.xoma.com/portfolio 15
Slide 16: XOMA's Broad Portfolio Without Spend
XOMA’S BROAD PORTFOLIO WITHOUT SPEND COMMERCIALIZED PHASE 3 PHASE 2 Further Development 2 Assets 3 Assets 28Assets Expenses by XOMA: PHASE 1/2 PHASE 1 PRECLINICAL $0 2 16 11+ >50% of assets with Large-cap partners Assets Assets Assets 16
Slide 17: Since 2017, XOMA's Portfolio Continues to Advance and Mature
SINCE 2017, XOMA’S PORTFOLIO CONTINUES TO ADVANCE AND MATURE PHASE 3 TO APPROVAL 1 PHASE 2 TO PHASE 3 4 PHASE 2A TO PHASE 2B 2 PHASE 1 TO PHASE 2 11 30 Advancements PHASE → PHASE ENTERED CLINIC 12 PRECLINICAL PHASE 1 PHASE 2 PHASE 3 APPROVAL 17
Slide 18: 2023: Potential Events from Our Partners
2023: POTENTIAL EVENTS FROM OUR PARTNERS S PO N S O R/ PROGRAM: Phase 1 Phase 2 Phase 3 Regulatory Medexus / IXINITY Pediatric Label Expansion filed Day One / tovorafenib Ph 2 pediatric low-grade glioma readout Ph 3 initiation NDA Filed Zevra / arimoclomol NDA Filed Rezolute / RZ358 Ph 2 completed -
Slide 19: Who We Are
WHO WE ARE Board of Directors ▪ Leadership ▪ Owen Hughes, Executive Chair XOMA – Owen Hughes, Executive Chair ▪ Heather L. Franklin – Brad Sitko, Chief Investment Officer Blaze BioScience – Tom Burns, Chief Financial Officer ▪ Natasha Hernday Seagen ▪ Business Development Team ▪ Barbara Kosacz Krono
Slide 20: Financial Highlights
FINANCIAL HIGHLIGHTS ($M) $100 Y/E Cash $90 $80 Expenses >$94M $70 in milestone $60 payments $50 since 2016 $40 $30 ~$1.1B $20 in potential $10 milestones $0 2016 2017 2018 2019 2020 2021 2022 20
Slide 21: Regulatory agencies in >70 countries approved Roche's VABYSMO
Regulatory agencies in >70 countries have granted commercialization approval to Roche’s VABYSMO® (faricimab) XOMA received >$2.9M on sales through 12/31/22 THE FIRST ASSET UNDER XOMA’S ROYALTY AGGREGATOR BUSINESS MODEL TO BE APPROVED Acquired economic rights from Affitech SA 21
Slide 22: What Makes XOMA So Exciting
WHAT MAKES XOMA SO EXCITING ▪ XOMA’s model demonstrates future potential through cash from commercial sales ‒ >$2.9M cash received from Roche’s VABYSMO®1 sales through 12/31/22 ‒ Receiving cashflows from IXINITY® sales ▪ Potential royalty stream on 70+ assets; pharmaceutical partners fund 100% of re
Slide 23: Corporate Presentation
CORPORATE PRESENTATION THE ROYALTY AGGREGATOR FOR BIOTECH NASDAQ: XOMA COMPANIES AUGUST 2023
Slide 24: Partner-Driven Clinical Events Achieved in 2021 & 2022
A SIGNIFICANT NUMBER OF PARTNER-DRIVEN CLINICAL EVENTS ACHIEVED IN 2021 & 2022 As disclosed by partners in public filings PHASE 1 PHASE 1/2 PHASE 2 PHASE 3 REGULATORY ▪ Bayer/osocimab: ▪ Incyte/INCAGN01876: Advanced Rezolute/RZ358: ▪ Novartis/NIS793: ▪ Roche/VABYSMO® ESRD completed malignancies comp